CO2021012267A2 - Composiciones de materia con actividad para eliminar lipofuscina de células retinales - Google Patents

Composiciones de materia con actividad para eliminar lipofuscina de células retinales

Info

Publication number
CO2021012267A2
CO2021012267A2 CONC2021/0012267A CO2021012267A CO2021012267A2 CO 2021012267 A2 CO2021012267 A2 CO 2021012267A2 CO 2021012267 A CO2021012267 A CO 2021012267A CO 2021012267 A2 CO2021012267 A2 CO 2021012267A2
Authority
CO
Colombia
Prior art keywords
compositions
activity
matter
retinal cells
lipofuscin
Prior art date
Application number
CONC2021/0012267A
Other languages
English (en)
Spanish (es)
Inventor
Marcelo M Nociari
Enrique Rodriguez Boulan
Original Assignee
Univ Cornell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Cornell filed Critical Univ Cornell
Publication of CO2021012267A2 publication Critical patent/CO2021012267A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16—Cyclodextrin; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Materials Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CONC2021/0012267A 2019-03-05 2021-09-20 Composiciones de materia con actividad para eliminar lipofuscina de células retinales CO2021012267A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962814028P 2019-03-05 2019-03-05
PCT/US2020/020805 WO2020180872A1 (en) 2019-03-05 2020-03-03 Compositions of matter with activity to remove lipofuscin from retinal cells

Publications (1)

Publication Number Publication Date
CO2021012267A2 true CO2021012267A2 (es) 2021-10-20

Family

ID=72337111

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0012267A CO2021012267A2 (es) 2019-03-05 2021-09-20 Composiciones de materia con actividad para eliminar lipofuscina de células retinales

Country Status (16)

Country Link
US (1) US20220118002A1 (https=)
EP (1) EP3934660A4 (https=)
JP (1) JP7573881B2 (https=)
KR (1) KR20210142651A (https=)
CN (1) CN113747902A (https=)
AU (1) AU2020232266A1 (https=)
BR (1) BR112021017529A2 (https=)
CA (1) CA3132466A1 (https=)
CO (1) CO2021012267A2 (https=)
EA (1) EA202192183A1 (https=)
IL (1) IL286002A (https=)
MX (1) MX2021010650A (https=)
PH (1) PH12021552131A1 (https=)
SG (1) SG11202109541YA (https=)
WO (1) WO2020180872A1 (https=)
ZA (1) ZA202106559B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3205822A1 (en) * 2021-01-22 2022-07-28 Marcelo M. NOCIARI Compositions and methods for the identification of compounds that protect against lipofuscin cytotoxicity
AU2023420130A1 (en) * 2022-12-30 2025-08-14 Cornell University Acid cyclodextrins for the treatment of lipofuscin buildups and ocular diseases
CN116253809B (zh) * 2023-04-19 2024-11-05 广州润虹医药科技股份有限公司 一种去除壳聚糖中内毒素的方法
WO2025147228A1 (en) * 2024-01-02 2025-07-10 Alkeus Pharmaceuticals, Inc. Treatment for asymptomatic stargardt disease patients with gildeuretinol acetate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
IL115849A0 (en) 1994-11-03 1996-01-31 Merz & Co Gmbh & Co Tangential filtration preparation of liposomal drugs and liposome product thereof
US8679511B2 (en) * 2009-10-01 2014-03-25 Duquesne University of the Holy Spririt In-situ gel ophthalmic drug delivery system of estradiol or other estrogen for prevention of cataracts
WO2011072141A1 (en) * 2009-12-11 2011-06-16 Neuron Systems, Inc. Compositions and methods for the treatment of macular degeneration
US10463687B2 (en) * 2011-01-20 2019-11-05 Cornell University Treatments for retinal disorders
KR101423631B1 (ko) * 2012-08-17 2014-07-25 주식회사파마킹 에스-알릴엘-시스테인을 유효성분으로 포함하는 안질환 예방 또는 치료용 조성물 및 이를 포함하는 의약제제
WO2014152959A1 (en) * 2013-03-14 2014-09-25 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
WO2016168772A1 (en) 2015-04-17 2016-10-20 Sens Research Foundation, Inc. Cyclodextrin compounds for the prevention and treatment of aging
GB2556082A (en) 2016-11-18 2018-05-23 Warneford Healthcare Ltd Ophthalmic composition

Also Published As

Publication number Publication date
EP3934660A4 (en) 2022-11-23
JP7573881B2 (ja) 2024-10-28
WO2020180872A1 (en) 2020-09-10
CA3132466A1 (en) 2020-09-10
PH12021552131A1 (en) 2022-08-22
KR20210142651A (ko) 2021-11-25
CN113747902A (zh) 2021-12-03
US20220118002A1 (en) 2022-04-21
EP3934660A1 (en) 2022-01-12
EA202192183A1 (ru) 2022-01-14
ZA202106559B (en) 2025-01-29
IL286002A (en) 2021-10-31
JP2022525007A (ja) 2022-05-11
AU2020232266A1 (en) 2021-09-23
SG11202109541YA (en) 2021-09-29
BR112021017529A2 (pt) 2021-11-09
MX2021010650A (es) 2021-12-10

Similar Documents

Publication Publication Date Title
CO2021012267A2 (es) Composiciones de materia con actividad para eliminar lipofuscina de células retinales
MX2020001340A (es) Modelos celulares y terapias para enfermedades oculares.
PH12019502058A1 (en) Farnesoid x receptor agonists and uses thereof
PH12018500586B1 (en) Farnesoid x receptor agonists and uses thereof
PH12017500746B1 (en) Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease
SG10201808258SA (en) Improved methods for manufacturing adoptive cell therapies
PH12017501217A1 (en) Methods of treating retinal diseases
WO2016029191A3 (en) Channel modulators
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
BR112017003711A2 (pt) artigo do tipo para vestir com cós elástico
EP4364743A3 (en) A modified release composition of orlistat and acarbose for the treatment of obesity and related metabolic disorders
PH12018501072A1 (en) Modified release orally administered amino acid formulations
MY190011A (en) Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
MX2021010886A (es) Uso de medicamentos para disminuir la evolucion de la enfermedad de parkinson.
WO2018134815A3 (en) Methods of treating neurodegenerative diseases by inducing disease-associated microglia (dam) cells
PH12020551573A1 (en) Pharmaceutical compositions for inhibiting inflammatory cytokines
SG11201806177QA (en) Transplant material for treatment of heart disease
MX2019002901A (es) Tratamiento de esclerosis multiple con chs-131.
MX2023008613A (es) Composiciones y metodos para la identificacion de compuestos que protegen contra la citotoxicidad de la lipofuscina.
BR112017003693A2 (pt) artigo do tipo para vestir com cós elástico
MX2020005603A (es) Imitadores mir29 para el tratamiento de la fibrosis ocular.
MX2019013207A (es) Metodos y composiciones para tratar la endometriosis y sintomas asociados a la endometriosis.
MX2022001772A (es) Formulaciones de isotretinoina y usos y metodos de las mismas.
WO2016144706A3 (en) Autotaxin inhibitor compounds and uses thereof
WO2016144704A3 (en) Heterocyclic autotaxin inhibitor compounds